Embecta Corp./$EMBC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Ticker
$EMBC
Sector
Primary listing
Employees
1,850
Headquarters
Website
Embecta Corp. Metrics
BasicAdvanced
$183m
1.64
$1.88
1.05
$0.46
1.29%
Price and volume
Market cap
$183m
Beta
1.05
52-week high
$15.55
52-week low
$2.77
Average daily volume
3.3m
Dividend rate
$0.46
Financial strength
Current ratio
2.459
Quick ratio
1.342
Long term debt to equity
-216.243
Total debt to equity
-216.85
Dividend payout ratio (TTM)
31.55%
Interest coverage (TTM)
2.79%
Profitability
EBITDA (TTM)
320.9
Gross margin (TTM)
61.84%
Net profit margin (TTM)
10.73%
Operating margin (TTM)
26.68%
Effective tax rate (TTM)
34.02%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
16.84%
Return on equity (TTM)
-16.43%
Valuation
Price to earnings (TTM)
1.64
Price to revenue (TTM)
0.174
Price to book
-0.29
Price to tangible book (TTM)
-0.28
Price to free cash flow (TTM)
0.887
Free cash flow yield (TTM)
112.72%
Free cash flow per share (TTM)
3.483
Dividend yield (TTM)
14.89%
Forward dividend yield
1.29%
Growth
Revenue change (TTM)
-3.43%
Earnings per share change (TTM)
111.16%
3-year revenue growth (CAGR)
-2.32%
3-year earnings per share growth (CAGR)
4.80%
3-year dividend per share growth (CAGR)
10.06%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Embecta Corp. News
AllArticlesVideos
Investor Notice: Robbins LLP Informs Investors of the Embecta Corp. Class Action Lawsuit
Business Wire·6 hours ago
EMBC Investors Have Opportunity to Join Embecta Corp. Fraud Investigation with the Schall Law Firm
Business Wire·2 days ago
Levi & Korsinsky Investigating Whether Embecta Corp. (EMBC) Misled Investors - Securities Law Violations Possible
Newsfile Corp·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs